Literature DB >> 19536548

Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy.

Silvia Sánchez-Ramón1, Juan Carlos Ravell, Inmaculada de la Torre, María Montoro, Margarita Rodríguez-Mahou, Luis Carreño-Pérez, Eduardo Fernández-Cruz, Francisco Javier López-Longo.   

Abstract

We report on a 44-year-old woman affected by dermatopolymyositis resistant to conventional therapies who experienced long-term clinical improvement and remission after treatment with intravenous polyvalent immunoglobulin in a weekly schedule followed by rituximab therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19536548     DOI： 10.1007/s00296-009-1000-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  11 in total

1.  Fatal HBV reactivation in a subject with anti-HBs and anti-HBc.

Authors:  Takeji Umemura; Kendo Kiyosawa
Journal:  Intern Med       Date:  2006-07-18       Impact factor: 1.271

Review 2.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

Review 3.  The role of high-dose immune globulin intravenous in the treatment of dermatomyositis.

Authors:  Marinos C Dalakas
Journal:  Int Immunopharmacol       Date:  2005-12-20       Impact factor: 4.932

Review 4.  Tolerability and safety of rituximab (MabThera).

Authors:  Eva Kimby
Journal:  Cancer Treat Rev       Date:  2005-07-28       Impact factor: 12.111

5.  Rituximab in the treatment of refractory dermatomyositis.

Authors:  Nicole Chiappetta; James Steier; Barry Gruber
Journal:  J Clin Rheumatol       Date:  2005-10       Impact factor: 3.517

Review 6.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.

Authors:  Jordan S Orange; Elham M Hossny; Catherine R Weiler; Mark Ballow; Melvin Berger; Francisco A Bonilla; Rebecca Buckley; Javier Chinen; Yehia El-Gamal; Bruce D Mazer; Robert P Nelson; Dhavalkumar D Patel; Elizabeth Secord; Ricardo U Sorensen; Richard L Wasserman; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2006-04       Impact factor: 10.793

Review 7.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

8.  Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients.

Authors:  G Flores; C Cunningham-Rundles; A C Newland; J B Bussel
Journal:  Am J Hematol       Date:  1993-12       Impact factor: 10.047

Review 9.  Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis.

Authors:  Marinos C Dalakas
Journal:  Curr Opin Neurol       Date:  2004-10       Impact factor: 5.710

10.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

Authors:  M C Dalakas; I Illa; J M Dambrosia; S A Soueidan; D P Stein; C Otero; S T Dinsmore; S McCrosky
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245
View more
  3 in total

Review 1.  Therapeutic approaches in myositis.

Authors:  Rohit Aggarwal; Chester V Oddis
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.686

Review 2.  Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.

Authors:  Linda Nalotto; Luca Iaccarino; Margherita Zen; Mariele Gatto; Elisabetta Borella; Marta Domenighetti; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

3.  Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.

Authors:  Fowzia Ibrahim; Ernest Choy; Patrick Gordon; Caroline J Doré; Alan Hakim; George Kitas; David Isenberg; Bridget Griffiths; Bryan Lecky; Kuntal Chakravarty; John Winer; Katalin Danko; Robert G Cooper; Beverley White-Alao; David L Scott
Journal:  Rheumatology (Oxford)       Date:  2014-11-27       Impact factor: 7.580
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.